FDA News Roundup: Astellas, Sanofi Pasteur, Orexigen, and More

Biopharmaceutical company Molecular Templates got a nod of approval from the FDA on its Investigational New Drug (IND) application for MT-3724 last week. MT-3724 is a next-generation immunotoxin compound that induces direct cell death by inactivating ribosomes in CD20-expressing cells. Now that approval has been granted, the company plans to launch a phase 1 clinical trial program for the drug candidate, investigating its potential as a monotherapy in refractory non-Hodgkin’s lymphoma. The study will be held at Memorial Sloan-Kettering Cancer Center and New York University’s Langone Medical Center, joined eventually by a site in an oncology center in Texas.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news